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Background
The enormous increase in the number of patients receiving antiretroviral therapy (ART) worldwide is a remarkable success story but also poses a considerable burden on resource-limited countries due to the cost of drugs, medical care and laboratory monitoring [1] .
As part of its public health approach, the World Health Organization (WHO) recommends non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART regimens for adult patients and for those failing first-line ART a boosted protease inhibitor (PI)-based second-line regimen [2, 3] . This approach has been adopted by many countries, including South Africa [4] . ART failure may be determined in different ways. Monitoring of HIV viral load detects failure very early and is more specific than clinical and immunological (CD4 count) monitoring; therefore routine viral load monitoring is the gold standard and recommended where available [2, 5] . However, the technical complexity of available viral load assays and their cost hamper access to viral load monitoring in most resource-limited settings [6, 7] .
Dried blood spots (DBS) prepared from blood obtained through skin pricks are widely used to diagnose HIV infection in infants [8] , and can also be used for viral load monitoring [7, 9, 10] , which may reduce overall cost and increase access. However the high cost of viral load testing still remains an obstacle.
Pooled viral load testing can save costs by reducing the number of tests needed [11, 12, 13] and can be combined with the use of DBS [14, 15] . However, a viral load value above a clinical threshold (in South Africa currently 1000 viral RNA copies/ml in line with current WHO guidelines) cannot ascertain the cause of treatment failure [16] , which may be due to suboptimal drug levels secondary to insufficient adherence or drug and food interactions etc., or due to drug resistant virus [14, 17] .
According to a recent WHO report, approximately 30% of patients failing first-line ART have no detectable resistance mutations [18] but are at risk of being unnecessarily switched to more costly and less well tolerated second-line ART regimens.
In resource-rich countries, antiretroviral drug resistance (ADR) testing is used to determine whether virological failure is due to drug resistance. However, although the need for ADR testing has been recognised, and despite recently published guidelines, a lack of testing capacity and budget constraints seriously hamper their application [19] .
Recently, a novel approach combining testing of pooled samples by qualitative PCR with sequencing of positive samples was proposed [20] . If a pool tests positive, each sample in that pool is tested individually with the same assay and any positive sample is sequenced using the amplified product. This approach is very elegant in that it is more affordable than individual viral load monitoring through the use of pooling and of a qualitative instead of a quantitative PCR, while providing valuable additional information on the presence of resistance mutations for those who are failing treatment.
Objectives
This study aimed to validate and adapt this approach for a Southern African setting, where HIV-1 subtype C is most prevalent, with the specific aim of determining the sensitivity and negative predictive value the qualitative PCR targeting partial reverse transcriptase for detection of virologic failure when 5 patient specimens are pooled, and to determine the prevalence of mutations detected by sequencing the PCR product of individual specimens from positive pools.
Study Design

Study Population
Samples received at the diagnostic virology laboratory of the National Health 
Specimens
Routine viral load testing, using the Abbott RealTime HIV-1 assay with a limit of detection of 40 copies/ml, was performed on all samples as requested and residual specimens then used for the study. A total of 300 samples were included, pooled into 60 pools of 5 samples each.
The person performing the study testing was blinded to the routine HIV viral load result which was revealed only once the pooled testing algorithm was completed.
Pooling of samples and nucleic acid extraction
Pools consisted of 100µl of each of 5 individual samples, resulting in a total pool volume of 500µl.Nucleic acid extraction from pooled samples was performed using the NucliSENS ® easyMAG ® system (Biomérieux, Marcy l'Etoile, France). Of an elution volume of 100µl, 5µl were used for reverse transcription and first-round PCR.
PCR amplification
Initially the primers from Tilghman [20] and a single-round PCR were used, but due to insufficient sensitivity for detecting viral loads below 10,000 copies/ml of HIV-1 subtype C from pooled specimens, this approach was abandoned and a new PCR designed and optimised.
This nested PCR uses previously described primers Mj3 and Mj4 [21] as outer primers and a new set of nested (inner) primers,4RT (amino acid position in RT 229
→ 236) and 5RT long C (amino acid position in RT 52 → 62) [22] .These were designed to amplify with high sensitivity a conserved region in HIV-1 group M viruses including subtype C, and for the short amplification product to allow efficient sequencing using the nested primers while including the most important resistancerelated mutations in the reverse transcriptase coding region (RT) of the pol gene.
Primer sequences and positions are shown in Table 1 . Taq polymerase and 2µl of amplified product from the first round. Thermal cycling was performed on the GeneAmp® PCR System 9700, Applied Biosystems (Foster City, CA, USA). The presence or absence of amplified product was assessed using agarose gel electrophoresis.
Deconvolution of positive pools and genotypic resistance testing
If a pool tested positive, all five individual samples contained in the pool were tested separately. For this, samples were re-extracted individually with the NucliSENS ® easyMAG ® system, using 100µl of sample and 100µl elution volume.
First and second round reactions were carried out as for the pooled testing. Any positive individual sample was subjected to standard Sanger sequencing using a validated in-house protocol (validated against the ABI Prism Dye Terminator Cycle sequencing kit), which has also been used in previous studies [17] and is currently the diagnostic method at Tygerberg Hospital, using the amplified second-round PCR product and 5RT long C and 4RT (the same forward and reverse primers used for second round amplification, respectively) as sequencing primers. The sequencing platform used was the 3130xl Genetic Analyzer, Applied Biosystems (Foster City, CA, USA). The Stanford HIV db Program, available fromhttp://hivdb.stanford.edu/, was used for sequence analysis and resistance interpretation. This allowed identification of the most common NNRTI and nucleoside reverse transcriptase inhibitors (NRTI) associated mutations [14, 17] . Table 1 shows the primer sequences as well as the kits and equipment used.
Evaluation of pooled testing results
After pooled testing, deconvolution of positive pools and genotypic resistance testing of individual positive samples, results were compared to routine HIV viral load test results. In South Africa, virologic failure is defined as a viral load of 1000 copies per millilitre or greater [3] . Table 2 shows the ART data for the study population. The majority of patients were on the current first-line ART regimen in South Africa, consisting of tenofovir, lamivudine and efavirenz.
Results
Twenty-two of the 60 pools were positive. Individual testing revealed 29 (9.7%) samples with a detectable viral load. Of these, 26 samples (8.7%) had viral loads of above 1000 viral RNA copies per millilitre and were therefore defined as failing ART.
Pooled testing detected 24 of those 26 patients.The two samples that were missed were retested using the pools and individually, confirming the lack of amplification.
Both patients were females on tenofovir-based ART regimens, with viral loads of 8596 copies/ml and 38542 copies/ml, respectively. For the latter, residual extract was available for standard genotyping, which confirmed this particular strain to be genotype C.
The negative predictive value of pooled testing was 99.3% and the sensitivity for detecting patients failing therapy 92%. Table 3 summarises the results of pooled testing.
Most positive samples did have antiretroviral drug resistance-associated mutations. Figure 1 and Figure 2 illustrate the prevalence of various resistance mutations detected for NRTI and NNRTI, respectively. Of the patients failing first-line ART, 83.3% had NRTI resistance and 91.7% had NNRTI resistance. The commonest NRTI mutations were M184V/I and K65R, with 75% and 25% among patients failing ART, respectively, while the commonest NNRTI mutation was K103N in 46% of failing patients.
Discussion
The pooled testing algorithm presented here was able to detect 24 of 26 adult patients failing first-line ART according to WHO and South African national criteria and provided drug resistance information on the failing patients.
Pooled viral load testing has been shown to decrease the cost of virological monitoring in adults on first-line ART who have a low prevalence of failure [14, 23] .
Qualitative rather than quantitative detection of failure has previously been shown to reduce the cost of virological monitoring [24] , and sequencing of the reverse transcriptase coding region of the pol gene alone likewise reduces costs compared to longer sequences [25] .
An approach that combines pooled testing, qualitative detection of virological failure and reverse trancriptase-only sequencing for detection of first-line NNRTI-based ART regimen failure was developed by Tilghman et al in 2012 [20] . Pools consisting of five individual specimens are tested by qualitative PCR, which could be followed by deconvolution of positive pools and sequencing of individual positive specimens.
In their study, deconvolution of positive pools was not done due to insufficient sample volumes, but this proof-of-principle experiment has shown promise in the USA [20] . However, this approach may in fact be needed more urgently in resourceconstrained settings where virological monitoring is not available widely at present.
We therefore validated this approach in a Southern African context, where HIV-1 subtype C is most prevalent and patient characteristics differ markedly from industrialised countries. We found poor amplification when using the primers from Tilghman et al, 2012, in our setting where subtype C dominates, which can be explained by too many mismatches when aligned with HIV-1 subtype C in silico. We therefore designed primers, 5RT long C and 4RT, primarily for subtype C but also considering other group M subtypes, as our inner primers, while using previously described primers, Mj3 and Mj4 [21] , as outer primers.
We were able to achieve a sensitivity of 92% and a positive predictive value of 89.7% for detecting patients who were failing ART according to WHO criteria (i.e.
with a viral load of > 1000 copies / ml), missing two patients out of a total of 26 with ART failure, with a specificity of 98.9%. The most likely reason for the lower sensitivity is probably primer-template mismatches, which are a common problem with amplification and sequencing of a highly divergent virus [26, 27] , where intraclade differences in the RT region for subtype C are nearly 6% [26] , possibly explaining the reason for the slightly lower sensitivity for detecting ART failure compared to the Tilghman study in North America, where subtype B is predominant.
However, with a negative predictive value of greater than 99%, and being able to provide drug resistance information for patients failing first-line ART, our study provides proof of principle that the concept developed by Tilghman et al. is viable in a Southern African context and possibly beyond. 70% of first-line ART failure cases, at least one drug resistance mutation was detected. Conversely, in the remaining 30%, no resistance mutations were detected [18, 28] . In countries where DRT is not available, these patients may have been switched unnecessarily to more expensive second-line treatment. Therefore, preventing the latter could potentially result in a cost saving.
In addition, some studies have shown that delaying switching to second-line ART after first-line failure is associated with increased risk of failing second-line ART, with poorer patient outcomes [29, 30] , whereas other studies suggest that NRTI resistance may not matter in this regard [31, 32] . This notwithstanding, there is uncertainty regarding the long term durability of second-line ART in the presence of significant NRTI resistance mutations.
One of the limitations of this study stems from a lack of a full cost effectiveness analysis. This would be needed in future to prove the cost benefit and convince policymakers in poorer countries that the qualitative pooling algorithm including resistance testing could allow for cheaper, more efficient, and more clinically useful ART monitoring.
Another limitation is that in the interest of sensitivity and sequencing using only two primers, two major reverse transcriptase resistance associated mutations were excluded: M41L, which confers low level resistance to AZT or D4T, and M230L, a major NNRTI mutation. In our setting, M41L occurs in only 2.8% of patients failing a first-line regimen containing a NNRTI and a thymidine analogue and was the only thymidine analogue mutation in only ¼ of these patients [17] . M230L occurs in 6.5%
of patients who fail an EFV-based regimen [17] , however it very rarely (0.1%) occurs as the only NNRTI mutation (G. van 
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